Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Current Assets: 2015-2024

Historic Current Assets for Spyre Therapeutics (SYRE) over the last 10 years, with Dec 2024 value amounting to $608.5 million.

  • Spyre Therapeutics' Current Assets rose 19.84% to $504.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $504.6 million, marking a year-over-year increase of 19.84%. This contributed to the annual value of $608.5 million for FY2024, which is 78.16% up from last year.
  • Latest data reveals that Spyre Therapeutics reported Current Assets of $608.5 million as of FY2024, which was up 78.16% from $341.5 million recorded in FY2023.
  • Spyre Therapeutics' Current Assets' 5-year high stood at $608.5 million during FY2024, with a 5-year trough of $62.3 million in FY2022.
  • Its 3-year average for Current Assets is $337.4 million, with a median of $341.5 million in 2023.
  • As far as peak fluctuations go, Spyre Therapeutics' Current Assets tumbled by 37.04% in 2022, and later surged by 448.57% in 2023.
  • Yearly analysis of 5 years shows Spyre Therapeutics' Current Assets stood at $149.8 million in 2020, then tumbled by 33.98% to $98.9 million in 2021, then crashed by 37.04% to $62.3 million in 2022, then spiked by 448.57% to $341.5 million in 2023, then surged by 78.16% to $608.5 million in 2024.